Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
MoonLake Immunotherapeutics (MLTX) had Consolidated Net Income/Loss of $-40.56M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-39.94M |
|
-- |
|
-- |
|
$47.48M |
|
$-47.48M |
|
$7.08M |
|
$-40.41M |
|
$-40.41M |
|
$-40.56M |
|
$-40.56M |
|
|
Consolidated Net Income/Loss |
$-40.56M |
$-40.56M |
|
$-47.48M |
|
$-47.11M |
|
63.23M |
|
63.23M |
|
$-0.63 |
|
$-0.63 |
|
| Balance Sheet Financials | |
$506.26M |
|
$0.71M |
|
$5.00M |
|
$511.26M |
|
$23.98M |
|
$73.02M |
|
$74.70M |
|
$98.68M |
|
$412.58M |
|
$412.58M |
|
$412.58M |
|
64.20M |
|
| Cash Flow Statement Financials | |
$-38.14M |
|
$56.25M |
|
$73.12M |
|
$180.43M |
|
$271.57M |
|
$91.14M |
|
$2.29M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
21.11 |
|
-- |
|
-- |
|
0.15 |
|
0.18 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-38.17M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-9.83% |
|
-9.83% |
|
-7.93% |
|
-8.35% |
|
$6.43 |
|
$-0.60 |
|
$-0.60 |
|